Background: Since the recognition of youth depression, numerous instruments have been developed, but there is little consensus regarding their use. In recent years, a national programme for outcome measurement has been introduced in the United Kingdom.
Method: A pragmatic literature search was conducted to select instruments commonly used to measure depression either in research or as recommended by UK national bodies.
Results: 15 depression rating scales were identified. Diagnostic instruments and rating scales are described.
Conclusions: Recent large depression trials have produced additional new data, and UK national organisations have made recommendations regarding the implementation of certain instruments.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/camh.12106 | DOI Listing |
Dermatol Ther (Heidelb)
January 2025
Department of Dermatology, University of Tsukuba, Tsukuba, Japan.
Introduction: Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score of ≥ 7 ("BARI itch dominant") have been characterized as an important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim to evaluate quality of life (QoL) and functioning outcomes in adult patients with BSA ≤ 40% and itch NRS ≥ 7 at baseline (BL) who received BARI 4 mg in the topical corticosteroid (TCS) combination trial BREEZE-AD7.
Materials: BREEZE-AD7 was a randomized, double-blind, placebo-controlled, parallel-group outpatient study involving adult patients with moderate-to-severe AD who received once-daily placebo or 2-mg or 4-mg BARI in combination with TCS for 16 weeks.
J Atten Disord
January 2025
Occupational Therapy Research Group (InTeO, Investigación en Terapia Ocupacional), Department of Surgery and Pathology, Miguel Hernandez University, Alicante, Spain.
Objective: To explore the association between telomere length (TL) and attention deficit hyperactivity disorder (ADHD) symptoms in children at 6-12 years.
Method: Data from 1,759 children belonging to the HELIX project cohorts and the Asturias, Gipuzkoa and Valencia cohorts of INMA project were included. TL was determined by blood sample using a PCR protocol.
J Psychoactive Drugs
January 2025
Department of Psychiatry, Mathison Centre for Mental Health Research and Education, and Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
The ever-changing landscape surrounding legality and accessibility of psychedelics and their increasing popularity make it imperative to better understand the nature of psychedelic use by the general population. To this end, 1,486 eligible respondents ( = 29.58, 67.
View Article and Find Full Text PDFThe study investigates the effectiveness of immersive virtual reality (VR) as a nonpharmaceutical approach to manage postoperative pain in patients following thoracoscopic surgery. In this single-center, triple-arm pilot randomized controlled trial (RCT), 61 postsurgical patients with a postoperative pain numerical rating scale (NRS) score ≥4 after receiving standard analgesia were included and assigned to either a quantum clinics-VR (QTC-VR) group, a Placebo-VR group, or a control group. The QTC-VR group engaged in a daily 10-minute interactive pain relief 3D-VR program, while the Placebo-VR group watched a daily 10-minute relaxation-based 2D film through VR headsets for three days following surgery.
View Article and Find Full Text PDFCurr Alzheimer Res
January 2025
Student's Scientific Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Background: Alzheimer's disease (AD) is a progressive neurodegenerative condition with rising prevalence due to the aging global population. Existing methods for diagnosing AD are struggling to detect the condition in its earliest and most treatable stages. One early indicator of AD is a substantial decrease in the brain's glucose metabolism.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!